Long term safety and efficacy of lowering LDL cholesterol with statin therapy: 20-year follow-up of West of Scotland coronary prevention study

Ford, I. , Murray, H., Mccowan, C. and Packard, C. J. (2016) Long term safety and efficacy of lowering LDL cholesterol with statin therapy: 20-year follow-up of West of Scotland coronary prevention study. Circulation, 133(11), pp. 1073-1080. (doi: 10.1161/CIRCULATIONAHA.115.019014) (PMID:26864092) (PMCID:PMC4894764)

116966.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.



Background—Extended follow up of statin-based low density lipoprotein (LDL) cholesterol lowering trials improves understanding of statin safety and efficacy. Examining cumulative cardiovascular events (total burden of disease) gives a better appreciation of the clinical value of statins. This paper evaluates the long-term impact of therapy on mortality and cumulative morbidity in a high risk cohort of men. Methods and Results—The West of Scotland Coronary Prevention Study was a primary prevention trial in 45-64 year old men with high LDL cholesterol. 6595 men were randomized to receive pravastatin 40mg once daily or placebo for an average of 4.9 years. Subsequent linkage to electronic health records permitted analysis of major incident events over 20 years. Post-trial statin use was recorded for 5 years post-trial, but not the last 10. Men allocated to pravastatin had reduced all-cause mortality; hazard ratio (HR) 0.87, 95% confidence interval (CI) 0.80-0.94, p=0.0007, mainly attributable to a 21% decrease in cardiovascular death; HR 0.79 (CI 0.69-0.90), p=0.0004. There was no difference in non-cardiovascular or cancer death rates between groups. Cumulative hospitalisation event rates were lower in the statin treated arm: by 18% for any coronary event (p=0.002), 24% for myocardial infarction (p=0.01) and 35% for heart failure (p=0.002). There were no significant differences between groups in hospitalization for non-cardiovascular causes. Conclusions—Statin treatment for five years was associated with a legacy benefit with improved survival and a substantial reduction in cardiovascular disease outcomes over a 20-year period, supporting the wider adoption of primary prevention strategies.

Item Type:Articles
Additional Information:The study was supported by a grant from Merck, Sharp & Dohme, Kenilworth, NJ, as part of an Investigator Initiated Program.
Glasgow Author(s) Enlighten ID:Murray, Mrs Heather and Ford, Professor Ian and Mccowan, Professor Colin and Packard, Professor Chris
Authors: Ford, I., Murray, H., Mccowan, C., and Packard, C. J.
College/School:College of Medical Veterinary and Life Sciences > School of Health & Wellbeing > Robertson Centre
College of Medical Veterinary and Life Sciences > School of Life Sciences
Journal Name:Circulation
Publisher:Lippincott Williams & Wilkins, Ltd.
ISSN (Online):1524-4539
Published Online:10 February 2016
Copyright Holders:Copyright © 2016 The Authors
First Published:First published in Circulation 133(11): 1073-1080
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record